These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 11600531)

  • 1. Prevention of bone loss with tibolone in postmenopausal women: results of two randomized, double-blind, placebo-controlled, dose-finding studies.
    Gallagher JC; Baylink DJ; Freeman R; McClung M
    J Clin Endocrinol Metab; 2001 Oct; 86(10):4717-26. PubMed ID: 11600531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double-blind, placebo-controlled study of the effects of tibolone on bone mineral density in postmenopausal osteoporotic women with and without previous fractures.
    Pavlov PW; Ginsburg J; Kicovic PM; van der Schaaf DB; Prelevic G; Bennink HJ
    Gynecol Endocrinol; 1999 Aug; 13(4):230-7. PubMed ID: 10533157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.
    McClung MR; Wasnich RD; Recker R; Cauley JA; Chesnut CH; Ensrud KE; Burdeska A; Mills T;
    J Bone Miner Res; 2004 Jan; 19(1):11-8. PubMed ID: 14753731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tibolone: prevention of bone loss in late postmenopausal women.
    Bjarnason NH; Bjarnason K; Haarbo J; Rosenquist C; Christiansen C
    J Clin Endocrinol Metab; 1996 Jul; 81(7):2419-22. PubMed ID: 8675554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of tibolone and fluoride displays a pronounced effect on bone mineral density in postmenopausal osteoporotic women.
    Reginster JY; Agnusdei D; Gennari C; Kicovic PM
    Gynecol Endocrinol; 1999 Oct; 13(5):361-8. PubMed ID: 10599554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of tibolone and raloxifene on bone mineral density in osteopenic postmenopausal women.
    Delmas PD; Davis SR; Hensen J; Adami S; van Os S; Nijland EA
    Osteoporos Int; 2008 Aug; 19(8):1153-60. PubMed ID: 18256777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tibolone and osteoporosis.
    Lazovic G; Radivojevic U; Milosevic V; Lazovic A; Jeremic K; Glisic A
    Arch Gynecol Obstet; 2007 Dec; 276(6):577-81. PubMed ID: 17605023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Postmenopausal hormonal treatment: conventional hormone replacement therapy or tibolone? Effects on bone].
    Reginster JY
    J Gynecol Obstet Biol Reprod (Paris); 2002 Oct; 31(6):541-9. PubMed ID: 12407324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study.
    Miller PD; Chines AA; Christiansen C; Hoeck HC; Kendler DL; Lewiecki EM; Woodson G; Levine AB; Constantine G; Delmas PD
    J Bone Miner Res; 2008 Apr; 23(4):525-35. PubMed ID: 18072873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.
    Jolly EE; Bjarnason NH; Neven P; Plouffe L; Johnston CC; Watts SD; Arnaud CD; Mason TM; Crans G; Akers R; Draper MW
    Menopause; 2003; 10(4):337-44. PubMed ID: 12851517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss.
    Gallagher JC; Fowler SE; Detter JR; Sherman SS
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3618-28. PubMed ID: 11502787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of postmenopausal bone loss at lumbar spine and upper femur with tibolone: a two-year randomised controlled trial.
    Beardsworth SA; Kearney CE; Purdie DW
    Br J Obstet Gynaecol; 1999 Jul; 106(7):678-83. PubMed ID: 10428524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, double-masked, 2-year comparison of tibolone with 17beta-estradiol and norethindrone acetate in preventing postmenopausal bone loss.
    Roux C; Pelissier C; Fechtenbaum J; Loiseau-Peres S; Benhamou CL
    Osteoporos Int; 2002 Mar; 13(3):241-8. PubMed ID: 11991445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of 8 years of treatment with tibolone 2.5 mg daily on postmenopausal bone loss.
    Rymer J; Robinson J; Fogelman I
    Osteoporos Int; 2001; 12(6):478-83. PubMed ID: 11446564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of conjugated estrogen plus medroxyprogesterone acetate versus tibolone in early postmenopausal Chinese women.
    Yang TS; Tsan SH; Chen CR; Chang SP; Yuan CC
    Zhonghua Yi Xue Za Zhi (Taipei); 1999 May; 62(5):308-15. PubMed ID: 10389286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of bone loss by clodronate in early postmenopausal women with vertebral osteopenia: a dose-finding study.
    Välimäki MJ; Laitinen K; Patronen A; Puolijoki H; Seppänen J; Pylkkänen L; Aranko SM; Sairanen S; Blåfield H; Rekiaro M; Väisänen K; Kormano M; Mäkinen L; Salmi J; Ala-Kaila K; Perttilä J; Vesterinen K; Koivunoro K;
    Osteoporos Int; 2002 Dec; 13(12):937-47. PubMed ID: 12459936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral hormone therapy with 17beta-estradiol and 17beta-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects.
    Greenwald MW; Gluck OS; Lang E; Rakov V
    Menopause; 2005; 12(6):741-8. PubMed ID: 16278618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 3-year study of prevention of postmenopausal bone loss: conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone.
    Thiébaud D; Bigler JM; Renteria S; Pache T; Welti HJ; Landry M; Burckhardt P
    Climacteric; 1998 Sep; 1(3):202-10. PubMed ID: 11907945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of tibolone on bone mineral density in postmenopausal women with osteopenia or osteoporosis--8 years follow-up.
    Prelevic GM; Markou A; Arnold A; Bartram C; Puzigaca Z; Ginsburg J
    Maturitas; 2004 Mar; 47(3):229-34. PubMed ID: 15036493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis: a multi-center, randomized, placebo-controlled clinical trial.
    Liu JL; Zhu HM; Huang QR; Zhang ZL; Li HL; Qin YJ; Zhang Y; Wei DL; Lu JH; Liu H; Chen XP; Liu YJ; Ekangaki A; Zheng YM; Diez-Perez A; Harper K
    Chin Med J (Engl); 2004 Jul; 117(7):1029-35. PubMed ID: 15265377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.